J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

Potential For Post-Tagrisso Therapy Niche

 
• By Alaric DeArment

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

lung illustration
J&J gets FDA speedy FDA approval for Rybrevant in non-small cell lung cancer with EGFR exon 20 insertion mutation • Source: Shutterstock

More from Immuno-oncology

More from Anticancer